Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Nitrogen containing other than solely as a nitrogen in an...
Reexamination Certificate
2007-04-10
2007-04-10
Gupta, Anish (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Nitrogen containing other than solely as a nitrogen in an...
C514S661000, C514S675000, C514S676000, C514S690000, C514S691000, C514S660000
Reexamination Certificate
active
09246307
ABSTRACT:
The present invention provides 4-substituted-2-azetidinone compounds, bicyclic 2-5-diketopiperazine compounds, and pharmaceutical compositions thereof that are potent, safe and effective neuroprotective agents. Due to their strong central nervous system (CNS) activity, the compounds can be used to enhance memory and to treat a variety of neurological disorders. The compounds are particularly useful for treating neurological disorders caused by, or associated with, CNS trauma.
REFERENCES:
patent: 5661150 (1997-08-01), Shirasaki et al.
patent: 5679679 (1997-10-01), Bowen et al.
patent: 5837706 (1998-11-01), Shirasaki et al.
patent: 5859001 (1999-01-01), Simpkins et al.
patent: 6787541 (2004-09-01), Gillespie et al.
patent: 6916835 (2005-07-01), Thatcher et al.
patent: 1583797 (1969-10-01), None
Patel et al. ‘Pharmacotherapy of Cognitive Impairment in Alzheimer's Disease: A Review’, J. of Geriatric Psychiatry and Neurobiology. vol. 8, pp. 81-95, Apr. 1995.
Martin et al. “Neurodegeneration in excitotoxicity, global cerebral ischemia, and target deprivation: A perspective on the contributions of apoptosis and necrosis,” Brain research bulletin, (Jul. 1, 1998) 46 (4) 281-309.
Mattson “Pathways towards and away from Alzheimer's Disease,” Nature. Aug. 5, 2004, vol. 430, pp. 631-639.
La Ferla et al., “The Alzeheimer's αβ peptide induces neurodegeneration and apoptotic cell death in transgenic mice”,Nature Genetics1995, 9, 21-30.
Eldadah et al., “The Role of CED-3-Related Cysteine Proteases in Apoptosis of Cerebellar Granule Cells”,J. Nueroscience1997, 17 (16), 6105-6113.
Su et al., “Immunohistochemical evidence for apoptosis in Alzheimer's disease”,NeuroReport1994, 5, 2529-2533.
Smucker, “Maximizing Function in Alzheimer's Disease: What Role for Tacrine”,American Family Physician1996, 645-652.
Ott et al., “Complementary and Alternative Medicines for Alzheimer's Disease”,J. of Geriatric Psychiatry and Neurobiology1998, 11, 163-173.
Ruther et al., “Sustained improvements in patients with dementia of Alzheimer's type (DAT) 6 months after termination of Cerebrolvsin therapy”,J. Neural Transmission2000, 107, 815-829.
Nalbantoglu et al., “Impaired learning and LTP in mice expressing the carboxy terminus of the Alzheimer amyloid precursor protein”,Nature1997, 387, 500-505.
Hsiao et al., “Correlative Memory Deficits, αβ Elevation, and Amyloid Plaques in Transgenic Mice”,Science1996, 274, 99-102.
D'Hooge et al., “Spatial learning deficit in mice expressing human 751-amino acid β-amyloid precursor protein”,NeuroReport1996, 2807-2811.
Graves et al., “The Association between Head Trauma and Alzheimer's Disease”,American J. Epidemiology1990, 131(3), 491-501.
Plassman et al., “Documented hear injury in early adulthood and risk of Alzheimer's disease and other dementias”,Neurology2000, 55, 1158.
Massimo Falorni, et al. “Chiral Ligands Containing Heteroatoms. 11.1Optically Active 2-Hydroxymethyl Piperazines as Catalysts in the Enantioselective Addition of Diethylzinc to Benzaldehyde”,Tetrahedron Asymmetry,vol. 4, No. 11, pp. 2389-2398, (1993).
Gamini S. Jayatilake, et al., “Metabolites from an Antarctic Sponge-Associated BacteriumPseudomonas aeruginosa”, J. Nat. Prod.,vol. 59, pp. 293-296, (1996).
List of 51 U.S. patents claiming neuroprotection.
Yakovlev, A. G., et al., “Mechanisms of Neural Cell Death: Implications for Development of Neuroprotective Treatment Strategies”, The American Society for Experimental NeuroTherapeutics, Inc., vol. 1-5, pp. 5-16, Jan. 2004.
Faden, A. I., et al., “Novel small peptides with neuroprotective and nootropic properties”, Journal of Alzheimer's Disease vol. 6 (2004) pp. S93-S97.
Faden, A. I., et al., “Novel Diketopiperazine Enhances Motor an dCognitive Recovery After Traumatic Brain Injury in Rats and Shows Neuroprotection In Vitro and In Vivo”, Journal of Cerebral Blood Flow & Metabolism, vol. 23, pp. 342-354.
Faden, A. I., et al., “Neuroprotective and Nootropic Actions of a Novel Cyclized Dipeptide After Controlled Cortical Impact Injury in Mice”, Journal of Cerebral Blood Flow & Metabolism, Vo. 23, pp. 355-363.
Faden, A. I., et al., “Neuroprotective effects of novel small peptides in vitro and after brain injury”, Laboratory for the Study of CNS Injury, Department of Neuroscience, Georgetown University of Medical Center, available at www.sciencedirect.com.
Araldi Gian Luca
Faden Alan I.
Kozikowski Alan P.
Georgetown University
Gupta Anish
Scully , Scott, Murphy & Presser, P.C.
LandOfFree
Cyclic dipeptides and azetidinone compounds and their use in... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cyclic dipeptides and azetidinone compounds and their use in..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cyclic dipeptides and azetidinone compounds and their use in... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3763227